Whole Cell Active Inhibitors of Mycobacterial Lipoamide Dehydrogenase Afford Selectivity over the Human Enzyme through Tight Binding Interactions.


Journal

ACS infectious diseases
ISSN: 2373-8227
Titre abrégé: ACS Infect Dis
Pays: United States
ID NLM: 101654580

Informations de publication

Date de publication:
12 02 2021
Historique:
pubmed: 3 2 2021
medline: 24 6 2021
entrez: 2 2 2021
Statut: ppublish

Résumé

Tuberculosis remains a leading cause of death from a single bacterial infection worldwide. Efforts to develop new treatment options call for expansion into an unexplored target space to expand the drug pipeline and bypass resistance to current antibiotics. Lipoamide dehydrogenase is a metabolic and antioxidant enzyme critical for mycobacterial growth and survival in mice. Sulfonamide analogs were previously identified as potent and selective inhibitors of mycobacterial lipoamide dehydrogenase

Identifiants

pubmed: 33527832
doi: 10.1021/acsinfecdis.0c00788
pmc: PMC7888283
doi:

Substances chimiques

Anti-Bacterial Agents 0
Dihydrolipoamide Dehydrogenase EC 1.8.1.4

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

435-444

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM118080
Pays : United States

Références

J Biol Chem. 2008 Jul 11;283(28):19329-41
pubmed: 18490451
Nat Rev Drug Discov. 2006 Sep;5(9):730-9
pubmed: 16888652
Mol Microbiol. 2005 Aug;57(3):859-68
pubmed: 16045627
Cell Host Microbe. 2011 Jan 20;9(1):21-31
pubmed: 21238944
FEBS J. 2015 May;282(10):1922-38
pubmed: 25703118
Chem Biol Drug Des. 2007 Feb;69(2):146-8
pubmed: 17381729
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11945-50
pubmed: 18697942
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Biochem J. 2009 May 13;420(2):259-65
pubmed: 19284385
J Biol Chem. 2005 Oct 7;280(40):33977-83
pubmed: 16093239
Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13673-13678
pubmed: 29229833
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
IUBMB Life. 2018 Sep;70(9):926-937
pubmed: 29934964
ACS Infect Dis. 2020 Apr 10;6(4):629-636
pubmed: 32011855
Nat Chem Biol. 2015 Jun;11(6):416-23
pubmed: 25894085
J Med Chem. 2004 Mar 25;47(7):1739-49
pubmed: 15027865
Chem Commun (Camb). 2010 Apr 21;46(15):2629-31
pubmed: 20461849
Biochem J. 1963 May;87:444-8
pubmed: 13949147
Science. 2002 Feb 8;295(5557):1073-7
pubmed: 11799204
Science. 2019 Jun 28;364(6447):1234-1235
pubmed: 31249047
Cell Host Microbe. 2008 Mar 13;3(3):137-45
pubmed: 18329613
Nature. 2000 Sep 14;407(6801):211-5
pubmed: 11001062
Biochemistry. 2010 Mar 2;49(8):1616-27
pubmed: 20078138
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Biochemistry. 2005 Dec 20;44(50):16574-83
pubmed: 16342948
Biochemistry. 2013 Dec 23;52(51):9375-84
pubmed: 24251446

Auteurs

John Ginn (J)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10065, United States.

Shan Sun (S)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10065, United States.

Mayako Michino (M)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10065, United States.

David J Huggins (DJ)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10065, United States.

Nancy Arango (N)

Structural Biology Program, Sloan Kettering Institute, New York, New York 10065, United States.

Christopher D Lima (CD)

Structural Biology Program, Sloan Kettering Institute, New York, New York 10065, United States.
Howard Hughes Medical Institute, New York, New York 10065, United States.

Nigel Liverton (N)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10065, United States.

Toshihiro Imaeda (T)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10065, United States.

Rei Okamoto (R)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10065, United States.

Takanobu Kuroita (T)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10065, United States.

Kazuyoshi Aso (K)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10065, United States.

Andrew Stamford (A)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10065, United States.

Michael Foley (M)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10065, United States.

Peter T Meinke (PT)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10065, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH